Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension

Hiroki Kabata, Toru Satoh, Masaharu Kataoka, Yuichi Tamura, Tomohiko Ono, Miyuki Yamamoto, H. Huqun, Koichi Hagiwara, Keiichi Fukuda, Tomoko Betsuyaku, Koichiro Asano

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and objective: Mutation of bone morphogenetic protein receptor type 2 (BMPR2) is a cause of pulmonary arterial hypertension (PAH). We measured the prevalence of this mutation and its impact on the phenotypes and long-term clinical outcomes in Japanese patients. Methods: Between 1999 and 2007, we consecutively enrolled and, until March 2012, followed 49 Japanese patients with PAH, including nine familial cases from seven families. We genotyped BMPR2, using direct sequencing and multiplex ligation-dependent probe amplification, to examine (i) the prevalence of BMPR2 mutations and gene rearrangement, (ii) the relationship between BMPR2 genotype and clinical phenotypes, and (iii) the long-term clinical outcomes of mutation carriers versus non-carriers under state-of-the-art medical therapy. Results: BMPR2 mutations were present in four of the seven families (57%) and in 14 of the 40 patients (35%) with sporadic PAH. The mean age at onset of PAH was 37.4 years in BMPR2 carriers, versus 25.9 years in non-carriers (P = 0.0025). The gender distribution and hemodynamic status at time of diagnosis were similar regardless of the mutation status. The 5-year survival rate after diagnosis of PAH was 88.5% in BMPR2 mutation carriers versus 80.9% in non-carriers (ns). Conclusions: The prevalence of BMPR2 mutations in Japanese with PAH was similar to that reported in other populations. At onset of PAH, BMPR2 mutation non-carriers were, on average, younger than carriers, possibly due to the heterogeneity of this subpopulation. With state-of-the-art therapy, the long-term survival of patients with PAH was high, regardless of the mutation status.

Original languageEnglish
Pages (from-to)1076-1082
Number of pages7
JournalRespirology
Volume18
Issue number7
DOIs
Publication statusPublished - 2013 Oct

Fingerprint

Type II Bone Morphogenetic Protein Receptors
Pulmonary Hypertension
Phenotype
Mutation
Art Therapy
Gene Rearrangement
Multiplex Polymerase Chain Reaction
Age of Onset

Keywords

  • bone morphogenetic protein receptor type 2
  • Japanese population
  • mutation
  • pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension. / Kabata, Hiroki; Satoh, Toru; Kataoka, Masaharu; Tamura, Yuichi; Ono, Tomohiko; Yamamoto, Miyuki; Huqun, H.; Hagiwara, Koichi; Fukuda, Keiichi; Betsuyaku, Tomoko; Asano, Koichiro.

In: Respirology, Vol. 18, No. 7, 10.2013, p. 1076-1082.

Research output: Contribution to journalArticle

Kabata, Hiroki ; Satoh, Toru ; Kataoka, Masaharu ; Tamura, Yuichi ; Ono, Tomohiko ; Yamamoto, Miyuki ; Huqun, H. ; Hagiwara, Koichi ; Fukuda, Keiichi ; Betsuyaku, Tomoko ; Asano, Koichiro. / Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension. In: Respirology. 2013 ; Vol. 18, No. 7. pp. 1076-1082.
@article{c1158ce8ca3d448493c9d8912b820bfe,
title = "Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension",
abstract = "Background and objective: Mutation of bone morphogenetic protein receptor type 2 (BMPR2) is a cause of pulmonary arterial hypertension (PAH). We measured the prevalence of this mutation and its impact on the phenotypes and long-term clinical outcomes in Japanese patients. Methods: Between 1999 and 2007, we consecutively enrolled and, until March 2012, followed 49 Japanese patients with PAH, including nine familial cases from seven families. We genotyped BMPR2, using direct sequencing and multiplex ligation-dependent probe amplification, to examine (i) the prevalence of BMPR2 mutations and gene rearrangement, (ii) the relationship between BMPR2 genotype and clinical phenotypes, and (iii) the long-term clinical outcomes of mutation carriers versus non-carriers under state-of-the-art medical therapy. Results: BMPR2 mutations were present in four of the seven families (57{\%}) and in 14 of the 40 patients (35{\%}) with sporadic PAH. The mean age at onset of PAH was 37.4 years in BMPR2 carriers, versus 25.9 years in non-carriers (P = 0.0025). The gender distribution and hemodynamic status at time of diagnosis were similar regardless of the mutation status. The 5-year survival rate after diagnosis of PAH was 88.5{\%} in BMPR2 mutation carriers versus 80.9{\%} in non-carriers (ns). Conclusions: The prevalence of BMPR2 mutations in Japanese with PAH was similar to that reported in other populations. At onset of PAH, BMPR2 mutation non-carriers were, on average, younger than carriers, possibly due to the heterogeneity of this subpopulation. With state-of-the-art therapy, the long-term survival of patients with PAH was high, regardless of the mutation status.",
keywords = "bone morphogenetic protein receptor type 2, Japanese population, mutation, pulmonary arterial hypertension",
author = "Hiroki Kabata and Toru Satoh and Masaharu Kataoka and Yuichi Tamura and Tomohiko Ono and Miyuki Yamamoto and H. Huqun and Koichi Hagiwara and Keiichi Fukuda and Tomoko Betsuyaku and Koichiro Asano",
year = "2013",
month = "10",
doi = "10.1111/resp.12117",
language = "English",
volume = "18",
pages = "1076--1082",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension

AU - Kabata, Hiroki

AU - Satoh, Toru

AU - Kataoka, Masaharu

AU - Tamura, Yuichi

AU - Ono, Tomohiko

AU - Yamamoto, Miyuki

AU - Huqun, H.

AU - Hagiwara, Koichi

AU - Fukuda, Keiichi

AU - Betsuyaku, Tomoko

AU - Asano, Koichiro

PY - 2013/10

Y1 - 2013/10

N2 - Background and objective: Mutation of bone morphogenetic protein receptor type 2 (BMPR2) is a cause of pulmonary arterial hypertension (PAH). We measured the prevalence of this mutation and its impact on the phenotypes and long-term clinical outcomes in Japanese patients. Methods: Between 1999 and 2007, we consecutively enrolled and, until March 2012, followed 49 Japanese patients with PAH, including nine familial cases from seven families. We genotyped BMPR2, using direct sequencing and multiplex ligation-dependent probe amplification, to examine (i) the prevalence of BMPR2 mutations and gene rearrangement, (ii) the relationship between BMPR2 genotype and clinical phenotypes, and (iii) the long-term clinical outcomes of mutation carriers versus non-carriers under state-of-the-art medical therapy. Results: BMPR2 mutations were present in four of the seven families (57%) and in 14 of the 40 patients (35%) with sporadic PAH. The mean age at onset of PAH was 37.4 years in BMPR2 carriers, versus 25.9 years in non-carriers (P = 0.0025). The gender distribution and hemodynamic status at time of diagnosis were similar regardless of the mutation status. The 5-year survival rate after diagnosis of PAH was 88.5% in BMPR2 mutation carriers versus 80.9% in non-carriers (ns). Conclusions: The prevalence of BMPR2 mutations in Japanese with PAH was similar to that reported in other populations. At onset of PAH, BMPR2 mutation non-carriers were, on average, younger than carriers, possibly due to the heterogeneity of this subpopulation. With state-of-the-art therapy, the long-term survival of patients with PAH was high, regardless of the mutation status.

AB - Background and objective: Mutation of bone morphogenetic protein receptor type 2 (BMPR2) is a cause of pulmonary arterial hypertension (PAH). We measured the prevalence of this mutation and its impact on the phenotypes and long-term clinical outcomes in Japanese patients. Methods: Between 1999 and 2007, we consecutively enrolled and, until March 2012, followed 49 Japanese patients with PAH, including nine familial cases from seven families. We genotyped BMPR2, using direct sequencing and multiplex ligation-dependent probe amplification, to examine (i) the prevalence of BMPR2 mutations and gene rearrangement, (ii) the relationship between BMPR2 genotype and clinical phenotypes, and (iii) the long-term clinical outcomes of mutation carriers versus non-carriers under state-of-the-art medical therapy. Results: BMPR2 mutations were present in four of the seven families (57%) and in 14 of the 40 patients (35%) with sporadic PAH. The mean age at onset of PAH was 37.4 years in BMPR2 carriers, versus 25.9 years in non-carriers (P = 0.0025). The gender distribution and hemodynamic status at time of diagnosis were similar regardless of the mutation status. The 5-year survival rate after diagnosis of PAH was 88.5% in BMPR2 mutation carriers versus 80.9% in non-carriers (ns). Conclusions: The prevalence of BMPR2 mutations in Japanese with PAH was similar to that reported in other populations. At onset of PAH, BMPR2 mutation non-carriers were, on average, younger than carriers, possibly due to the heterogeneity of this subpopulation. With state-of-the-art therapy, the long-term survival of patients with PAH was high, regardless of the mutation status.

KW - bone morphogenetic protein receptor type 2

KW - Japanese population

KW - mutation

KW - pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=84884837977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884837977&partnerID=8YFLogxK

U2 - 10.1111/resp.12117

DO - 10.1111/resp.12117

M3 - Article

VL - 18

SP - 1076

EP - 1082

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 7

ER -